Published in Psychoneuroendocrinology on February 19, 2010
Identification of functional differences between recombinant human α and β cardiac myosin motors. Cell Mol Life Sci (2012) 1.06
Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci (2012) 0.97
Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology (2012) 0.93
Sex differences in activation of the hypothalamic-pituitary-adrenal axis by methamphetamine. J Neurochem (2014) 0.89
The clinical implications of mouse models of enhanced anxiety. Future Neurol (2011) 0.89
Chronic ethanol potentiates the effect of neuropeptide s in the basolateral amygdala and shows increased anxiolytic and anti-depressive effects. Neuropsychopharmacology (2012) 0.82
Identification of a role for the ventral hippocampus in neuropeptide S-elicited anxiolysis. PLoS One (2013) 0.81
In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. Pharmacol Res Perspect (2015) 0.80
The role of neuropeptide S and neuropeptide S receptor 1 in regulation of respiratory function in mice. Peptides (2010) 0.79
The genetics of anxiety-related negative valence system traits. Am J Med Genet B Neuropsychiatr Genet (2016) 0.79
Developmental methamphetamine exposure results in short- and long-term alterations in hypothalamic-pituitary-adrenal-axis-associated proteins. Dev Neurosci (2013) 0.78
Post-training gamma irradiation-enhanced contextual fear memory associated with reduced neuronal activation of the infralimbic cortex. Behav Brain Res (2015) 0.76
Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation. Psychopharmacology (Berl) (2012) 0.76
Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors. Virchows Arch (2014) 0.75
Immediate and lasting effects of chronic daily methamphetamine exposure on activation of cells in hypothalamic-pituitary-adrenal axis-associated brain regions. Psychopharmacology (Berl) (2015) 0.75
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther (1977) 8.46
Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc (2006) 7.64
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol (2003) 7.47
The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev (2005) 4.64
Characterization of a common susceptibility locus for asthma-related traits. Science (2004) 4.05
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 3.61
Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) (2001) 2.44
Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology (Berl) (1994) 2.33
The transcription factor gene Nfib is essential for both lung maturation and brain development. Mol Cell Biol (2005) 2.09
Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci (2006) 2.01
Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol (2007) 1.95
Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther (2005) 1.81
Stress and inflammation in exacerbations of asthma. Brain Behav Immun (2007) 1.80
What is the Most Sensitive Measure of Water Maze Probe Test Performance? Front Integr Neurosci (2009) 1.56
Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology (2006) 1.49
Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J Pharmacol Exp Ther (2008) 1.47
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) (2008) 1.41
Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci (2003) 1.36
The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci (2001) 1.36
Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I. J Biol Chem (2006) 1.32
Refining the critical period for methamphetamine-induced spatial deficits in the Morris water maze. Psychopharmacology (Berl) (2003) 1.26
Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology (2007) 1.24
Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.23
Peptide S is a novel potent inhibitor of voluntary and fast-induced food intake in rats. Biochem Biophys Res Commun (2005) 1.23
Bayesian analysis of a previously published genome screen for panic disorder reveals new and compelling evidence for linkage to chromosome 7. Am J Med Genet B Neuropsychiatr Genet (2003) 1.20
Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice. Eur J Neurosci (2005) 1.09
Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides (2008) 1.08
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res (2007) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Centrally administered neuropeptide S activates orexin-containing neurons in the hypothalamus and stimulates feeding in rats. Endocrine (2006) 1.01
Results of a genome-wide genetic screen for panic disorder. Am J Med Genet (1998) 1.01
Genomewide survey of panic disorder. Am J Med Genet (2001) 0.99
Mouse behavioural analysis in systems biology. Biochem J (2005) 0.99
Characterization of GPRA, a novel G protein-coupled receptor related to asthma. Am J Respir Cell Mol Biol (2005) 0.95
Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatr Scand Suppl (2000) 0.92
Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice. Neurosci Lett (2009) 0.86
Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome. Curr Mol Med (2008) 0.85
Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology (2000) 0.84
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med (2012) 8.24
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
The knockout mouse project. Nat Genet (2004) 7.80
Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc (2006) 7.64
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell (2004) 7.60
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol (2003) 7.47
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 6.79
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 5.48
Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 5.29
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Eosinophilic esophagitis. N Engl J Med (2004) 4.43
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest (2003) 4.08
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A (2004) 4.06
Eosinophils: biological properties and role in health and disease. Clin Exp Allergy (2008) 3.92
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology (2006) 3.68
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol (2006) 3.51
Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2012) 3.45
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med (2002) 3.36
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol (2007) 3.24
Lhx6 delineates a pathway mediating innate reproductive behaviors from the amygdala to the hypothalamus. Neuron (2005) 3.21
Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am J Pathol (2006) 3.18
Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med (2005) 3.18
RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology (2008) 3.13
F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol (2006) 3.13
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol (2009) 3.03
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer (2007) 2.96
MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol (2009) 2.89
Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metab (2005) 2.75
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med (2010) 2.75
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol (2006) 2.74
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med (2006) 2.67
Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife (2013) 2.66
Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A (2012) 2.62
Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol (2004) 2.58
Alternatively activated macrophage-derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. J Exp Med (2009) 2.51
Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol (2007) 2.50
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2. J Immunol (2009) 2.44
Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology (2003) 2.40
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Foxa2 regulates alveolarization and goblet cell hyperplasia. Development (2004) 2.35
Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev (2004) 2.32
Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem (2004) 2.32
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol (2003) 2.31
Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest (2002) 2.26
Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A (2004) 2.23
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med (2008) 2.19
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol (2007) 2.18
Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest (2003) 2.17
Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol (2008) 2.12
Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci U S A (2010) 2.06